Icotrokinra Tablets 200 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 200 mg

Reference Brands: Icotyde (Johnson & Johnson)

Icotrokinra (Icotyde, Johnson & Johnson) is a once-daily tablet that blocks the IL-23 receptor, approved by the US FDA in March 2026 for moderate to severe plaque psoriasis. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers, API makers and licensees preparing for patent expiry.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Icotrokinra Tablets? List it or send an offer →

Product Description:

Icotrokinra is a peptide that blocks the interleukin-23 (IL-23) receptor. IL-23 drives the immune pathway behind psoriasis, and antibodies against it (guselkumab, risankizumab, tildrakizumab) are among the most effective psoriasis treatments, but they are injected. Icotrokinra was designed to survive the gut and act on the same pathway from a 200 mg tablet taken once a day.

The US FDA approved icotrokinra as Icotyde in March 2026 for moderate to severe plaque psoriasis in adults and in children aged 12 and over who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. It was discovered with Protagonist Therapeutics and is developed by Johnson & Johnson, which is also studying it in psoriatic arthritis and ulcerative colitis.

Sourcing and licensing notes. Icotrokinra is patented and only Johnson & Johnson makes it; there is no generic. We confirm registration status for each destination, handle enquiries for authorised supply of Icotyde where import is allowed, and connect developers and licensees interested in oral IL-23 therapy ahead of patent expiry.

How Icotrokinra Tablets is supplied today, and licensing ahead of patent expiry

Icotrokinra Tablets is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Icotrokinra Tablets, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Icotrokinra Tablets supply →

Back to Listing